Ono Pharmaceutical Co., Ltd. Overview
Pro stress-test →Ono Pharmaceutical is one of the largest pharmaceutical companies in Japan, with a diversified portfolio spanning oncology, cardiovascular, respiratory, and metabolic diseases. The company offers flagship products including Opdivo for malignant tumors and Kyprolis for cancer treatment, positioning itself as a meaningful player in global pharmaceutical markets.
Strategic Profile
Pro stress-test →Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe, with a balanced pipeline across multiple therapeutic areas rather than dependence on single blockbuster drugs.
Competitive Landscape
Pro stress-test →Ono's portfolio includes medicines for type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, Alzheimer's disease, and respiratory conditions. The company competes against major global pharma firms in oncology (particularly with Opdivo) and regional players in traditional therapeutic areas, with competitive positioning strengthened by established product franchises in circulatory and respiratory segments.
Industry Context
Ono Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Healthcare.
Key facts
Founded: 1717 · Headquarters: Osaka, Japan · Employees: 4,287 · Revenue: $3.4B · Market cap: $7.7B